stella
beta
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies — Stella
Recruiting
Back to Lymphoma, Nonhodgkin trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Prince of Wales Hospital, Hong Kong
View full record on ClinicalTrials.gov